Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)


İÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., Saip P., ...Daha Fazla

BREAST CANCER, cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 5
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s12282-013-0506-y
  • Dergi Adı: BREAST CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.480-485
  • Anahtar Kelimeler: Adjuvant treatment, Nine weeks trastuzumab, Cardiotoxicity, Early breast cancer, CHEMOTHERAPY, XENOGRAFTS, ANTIBODY, RECEPTOR, THERAPY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey.